Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers
Conclusions
Combination temsirolimus/metformin was well tolerated with modestly promising effectiveness among this heavily pretreated patient cohort. We recommend a dose of temsirolimus 25 mg weekly and metformin 2000 mg daily for phase II study.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer of the Uterus | Carcinosarcoma | Chemotherapy | Colorectal Cancer | Drugs & Pharmacology | Endometrial Cancer | Fortamet | Metformin | Ovarian Cancer | Ovaries | Renal Failure | Sarcomas | Study | Toxicology